TriangleNCT04537715 · OUTCOME
Part 2: Tmax of Tazemetostat and EPZ-6930 After Tazemetostat Alone at Steady-State
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- hour
- Interval / dispersion
- Geometric Coefficient of Variation
- Time frame
- Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose on Cycle 1 Day 15
What was measured
Blood samples were collected at specified timepoints. Tmax was assessed using non-compartmental data analysis method.
Analysis population: The PK population included all participants who had sufficient PK concentration data to calculate steady-state PK parameters in Part 2 and did not have any major protocol deviation that was deemed to greatly alter the steady-state exposure to tazemetostat or rifampin.
Groups in this outcome
Part 2: Tazemetostat
Participants received a single oral dose of 800 mg tazemetostat on Cycle 1 Day 1, BID dose of 800 mg of tazemetostat from Days 3 to 14 and a single oral dose of 800 mg tazemetostat on Day 15. From Days 17 to 23, they received an 800 mg BID dose of tazemetostat. On Day 24, subjects received a single dose of 800 mg tazemetostat. Participants continued to receive tazemetostat treatment at the recommended therapeutic dose (oral 800 mg tazemetostat BID), from Day 27 (Cycle 2 Day 1) for each subsequent cycle of 28-day duration until Investigator assessed clinical progression per standard practice, unacceptable treatment related toxicity/withdrawal; survival follow-up (until death/study closure).
| Group | Source count |
|---|---|
| Part 2: Tazemetostat | 16 |
Reported measurements
Tazemetostat
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: Tazemetostat | 1.25 | 47.0 | Not reported | Not reported | Not reported |
EPZ-6930
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: Tazemetostat | 1.47 | 59.1 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 47.0
- value
- 1.25
- title
- Tazemetostat
- categories
- measurements
- group Id
- OG000
- spread
- 59.1
- value
- 1.47
- title
- EPZ-6930
- denoms
- counts
- group Id
- OG000
- value
- 16
- units
- Participants
- description
- Blood samples were collected at specified timepoints. Tmax was assessed using non-compartmental data analysis method.
- dispersion Type
- Geometric Coefficient of Variation
- groups
- description
- Participants received a single oral dose of 800 mg tazemetostat on Cycle 1 Day 1, BID dose of 800 mg of tazemetostat from Days 3 to 14 and a single oral dose of 800 mg tazemetostat on Day 15. From Days 17 to 23, they received an 800 mg BID dose of tazemetostat. On Day 24, subjects received a single dose of 800 mg tazemetostat. Participants continued to receive tazemetostat treatment at the recommended therapeutic dose (oral 800 mg tazemetostat BID), from Day 27 (Cycle 2 Day 1) for each subsequent cycle of 28-day duration until Investigator assessed clinical progression per standard practice, unacceptable treatment related toxicity/withdrawal; survival follow-up (until death/study closure).
- id
- OG000
- title
- Part 2: Tazemetostat
- param Type
- GEOMETRIC_MEAN
- population Description
- The PK population included all participants who had sufficient PK concentration data to calculate steady-state PK parameters in Part 2 and did not have any major protocol deviation that was deemed to greatly alter the steady-state exposure to tazemetostat or rifampin.
- reporting Status
- POSTED
- time Frame
- Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours post-dose on Cycle 1 Day 15
- title
- Part 2: Tmax of Tazemetostat and EPZ-6930 After Tazemetostat Alone at Steady-State
- type
- SECONDARY
- unit Of Measure
- hour
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice